GlassScriptPhysician profile
Shawn D Burton
NPI 1720023096
$15,507.78
in general payments reported to CMS, 2019-2025
55 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,318 · 2020: $1,392 · 2021: $1,871 · 2022: $1,904 · 2023: $2,633 · 2024: $2,468 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,866 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,866.35 |
| Education | $157.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,148.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $3,036.02 | 2020-2025 | Vraylar, Mavyret, Linzess |
| Novo Nordisk INC | $1,059.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $898.91 | 2021-2025 | |
| Lilly USA, LLC | $686.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.45 | 2019-2024 | Trulance |
| Pfizer INC. | $581.76 | 2019-2025 | |
| Gilead Sciences, INC. | $578.50 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $388.18 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $376.61 | 2019-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $359.85 | 2023-2025 | Apretude |
| Teva Pharmaceuticals USA, INC. | $319.82 | 2019-2025 | Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $295.75 | 2024-2025 | Ingrezza |
| Amgen INC. | $246.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $241.15 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.